newsfilter
← Latest News
Business Wire·

Auna Announces 3Q26 Financial Results

  • Auna reported 10% FX-neutral & 19% reported revenue growth for 3Q26, reaching S/1,325 million.
  • Adjusted EBITDA decreased 4.6% FX-neutral to S/231 million, resulting in a 17.5% margin.
  • Mexico Segment Adjusted EBITDA grew 5% year-over-year in local currency, marking its first YoY growth in 2026.
  • Peru Adjusted EBITDA declined 6% in local currency due to penalties from prior receivable reconciliations & higher pharmacy/payroll costs.
  • Colombia Adjusted EBITDA fell 30% in local currency driven by adverse medical costs from a specific oncology risk-sharing contract & regulatory price caps.
  • Net Cash from Operating Activities increased 62% year-over-year to S/713 million, while Free Cash Flow rose 95% to S/626 million.
  • Leverage ratio improved to 3.5x, moving closer to the medium-term target of below 3.0x.
  • Consolidated Net Income was S/24 million, down from S/53 million in 3Q25, primarily due to the absence of a prior-year S/40 million non-cash FX gain.
  • Number of surgeries increased 12% year-over-year to 23,932, while chemotherapy & radiotherapy sessions rose 7%.
  • Oncology Medical Loss Ratio (MLR) remained stable at 50.7%.
  • Revenue growth was recorded across all markets: 16% in Mexico, 6% in Peru, & 12% in Colombia.
  • Auna terminated an oncology risk-sharing contract in Colombia that represented approximately 4% of revenues to limit exposure.
  • Construction began on the Centro Ambulatorio Trecca in Lima, a capital-light public-private partnership.
  • Full-year 2026 revenue guidance remains unchanged with expected FX-neutral growth of 10% to 14%.
  • Full-year 2026 Adjusted EBITDA guidance is revised to remain broadly stable or slightly down year-over-year.
  • Capital expenditure guidance remains unchanged at approximately 4% of revenues.